China
Africa
Explore chapters and articles related to this topic
The Use of Capillaroscopy and Aggregometry Methods to Diagnose the Alterations of Microcirculation and Microrheology in Diabetes
Published in Andrey V. Dunaev, Valery V. Tuchin, Biomedical Photonics for Diabetes Research, 2023
Andrei E. Lugovtsov, Yury I. Gurfinkel, Petr B. Ermolinskiy, Anastasia A. Fabrichnova, Alexander V. Priezzhev
Numerous studies show that the viscosities of whole blood, as well as those of plasma, measured at different shear rates in patients suffering from DM are significantly different from the norm [9,15,16]. Hyperglycemia increases blood osmolarity, which leads to increased capillary permeability, which increases hematocrit and blood viscosity. In addition, hyperglycemia can cause osmotic diuresis, thus reducing plasma volume and increasing hematocrit. High hematocrit levels have been shown to be associated with a decreased blood flow in the retina [17]. According to Ref. [18], hematocrit and blood viscosity decrease with an improved glycemic control in patients suffering from DM.
Bone Marrow Cell Counting: Methodological Issues
Published in Adrian P. Gee, BONE MARROW PROCESSING and PURGING, 2020
Elizabeth J. Read, Charles S. Carter, Herbert M. Cullis
Hematocrit, defined as the fraction of the blood occupied by the red blood cells, or packed cell volume, may be measured by simple manual methods involving centrifugation of a small volume of the blood or marrow sample in tubes of 3 mm diameter or capillary tubes.21 Automated cell counters can reliably calculate hematocrit from measurements of the red cell number and the mean corpuscular volume (MCV).20 Automated methods have a high degree of accuracy, equivalent to carefully done manual methods, and a somewhat high degree of precision.20 Although the nucleated cell count of the bone marrow is of prime interest in marrow processing laboratories, the hematocrit is especially important for three applications: (1) to estimate the packed cell volume of the initial harvest, which may require adjustment to optimize the efficiency of some automated processing procedures;27 (2) to estimate the red cell content of an ABO-incompatible bone marrow after procedures to eliminate red cells; and (3) to estimate the red cell content of marrows requiring purging procedures, such as 4-hydroperoxycyclophosphamide (4-HC) purging, that require careful control of the red cell content for optimal results.28
Clinical profile in adult typhoid fever in patients at hospital X, East Jakarta, Indonesia, January–March 2018
Published in Ade Gafar Abdullah, Isma Widiaty, Cep Ubad Abdullah, Medical Technology and Environmental Health, 2020
Table 9 and Figure 10 show that of the 84 patients who underwent hematocrit examination, 34 (40.48%) had low hematocrit levels, 48 (57.14%) had normal levels, and 2 (2.38%) had high levels.
Calcium-phosphate homeostasis in secondary progressive multiple sclerosis patients during mitoxantrone therapy
Published in Neurological Research, 2021
Martyna Lis, Natalia Niedziela, Maria Nowak-Kiczmer, Katarzyna Kubicka-Bączyk, Monika Adamczyk-Sowa
Another commonly known adverse effect of MTX therapy is cardiotoxicity, which was observed by a decline in the ejection fraction (EF) in patients at the end of our study [4–6]. This is confirmed by the results of other studies additionally pointing to a more frequent occurrence of cardiomyopathy and congestive heart failure [31]. It is probably explained by the ability of the drug to induce the formation of chelating compounds with iron ions that stimulate the formation of reactive oxygen species that damage cardiomyocytes [32]. Contrary to our results, Pastuszak et al. did not show a significant reduction in the left ventricular ejection fraction (LVEF) during MTX treatment and indicated the need for more detailed studies of the subject. Moreover, a study by Mincu et al. on MS patients who did not receive MTX therapy or did not present with primary heart disease indicated that the left ventricular systolic and diastolic functions were impaired due to a cardiac autonomic dysfunction [31,33] compared to the control group. Furthermore, we observed a reduced hematocrit (HCT) level in the study group during the treatment.
Novel agents for the treatment of polycythemia vera: an insight into preclinical research and early phase clinical trials
Published in Expert Opinion on Investigational Drugs, 2020
The other promising therapy, particularly in low risk patients, is through augmentation of the iron metabolism pathway through the pharmacologically derived iron deficiency restrictive erythropoiesis through a mini-hepcidin. This could provide ideal hematocrit control without the need for phlebotomy particularly for those patients fearful of the procedure, or for whom the repeat procedural necessity demands a significant time commitment. Lack of human clinical trials limits the ability to discuss key findings at this time. Major issues this agent must answer in future studies include the duration of treatment necessary to effectively reduce and control hematocrit compared to traditional phlebotomy. Additionally, long term thrombosis risk will need to be assessed and compared to traditional phlebotomy, as the thrombogenesis in myeloproliferative neoplasms is not attributable to hematocrit alone.
Accuracy and user performance evaluation of a blood glucose monitoring system which wirelessly transmits results to compatible insulin pumps
Published in Current Medical Research and Opinion, 2020
Michael Caswell, Daniel Brown, Joy Frank, Jane F. Wallace, Scott Pardo
Results from subject-obtained capillary fingertip blood samples were analyzed from 110 subjects. For the primary analysis (each subject testing two of the three test strip lots), there was a total of 220 evaluable results from the subject fingertip capillary samples, 220 evaluable results from the trial nurse-obtained fingertip capillary samples, and 209 evaluable results from the palm samples. For the post-hoc analysis of the first fingertip capillary sample only, there was a total of 110 evaluable results. The blood glucose concentration of the subjects’ blood samples, as measured by YSI, ranged from 69.1 mg/dL (3.8 mmol/L) to 521.5 mg/dL (28.9 mmol/L). Hematocrit measurements were performed in duplicate for each subject; average hematocrit values ranged from 24% to 53%, with a mean of 42%.